Suzhou Fengbei Biotech Stock603334.SHValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 19, 2026, Suzhou Fengbei Biotech Stock (603334.SH) trades at a P/E of 33.60x, P/B of 2.67x, P/S of 0.98x, and a dividend yield of 1.09%.
Longitudinal percentile comparison: P/E sits at the 33rd percentile over the trailing 10Y window (vs. 33rd percentile over 3Y); P/B sits at the 23rd percentile over the trailing 10Y window (vs. 23rd percentile over 3Y); P/S sits at the 20th percentile over the trailing 10Y window (vs. 20th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 65th percentile within its industry and the 46th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.09%, ranking at the 80th percentile over the trailing 20Y window.
The P/E and P/B long-window percentiles differ by only 9.8 points, pointing to a consistent valuation read across both metrics. Relative to the broader market, its P/E shows a deeper discount than it does against industry peers. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Suzhou Fengbei Biotech Stock operates in the Electricity and Public Utilities sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHA: 603334 · SSE: 603334 · 603334
Want the full picture on whether Suzhou Fengbei Biotech Stock (603334.SH) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 33.60 | ||||||
| P/B (MRQ) | 2.67 | ||||||
| P/S (TTM) | 0.98 | ||||||
| Dividend Yield | 1.09% | ||||||
| Buyback + Div Yield | 1.09% |